Theraclion SA ALTHE
EURONEXT · France · Health Technology
€0.6800-0.01 (-2.02%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
MALAKOFF, France, September 16, 2026--Regulatory News: THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive treatment of varicose veins using High-Intensity Focused Ultrasound (HIFU), today reports its results for the first half ended 30 June 2026, approved by the Board of Directors on 15 September 2026, ahead of the FDA decision on the De Novo submission for Sonovein®, expected between the end of the third quarter and th
MALAKOFF, France, August 20, 2026--Regulatory News: Theraclion (Paris:ALTHE):
MALAKOFF, France, July 23, 2026--Regulatory News: THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), today reports on its progress during the first half of 2026.
MALAKOFF, France, July 15, 2026--Regulatory News: Theraclion (Paris:ALTHE):
MALAKOFF, France, July 09, 2026--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), announces that its Board of Directors, which met on July 8, 2026, has appointed Mr. Vincent Gardès as Chairman of the Board of Directors, with immediate effect.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.